Get the Stockscreener App
6.30
4.65%
0.28
Karyopharm Therapeutics Inc stock is traded at $6.30, with a volume of 112.18K.
It is up +4.65% in the last 24 hours and up +61.95% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$6.02
Open:
$6.03
24h Volume:
112.18K
Relative Volume:
0.77
Market Cap:
$54.63M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.5753
EPS:
-10.95
Net Cash Flow:
$-102.89M
1W Performance:
+6.42%
1M Performance:
+61.95%
6M Performance:
-29.81%
1Y Performance:
-46.65%
1-Day Range:
$6.03
$6.5199
1-Week Range:
$5.49
$7.01
52-Week Range:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.30 | 48.47M | 137.27M | -123.57M | -102.89M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
AI Indicators Detect Buy Opportunity in Karyopharm Therapeutics Inc.July 2025 Action & Daily Stock Trend Watchlist - beatles.ru
Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain - MSN
Will Karyopharm Therapeutics Inc. benefit from rate cutsJuly 2025 Fed Impact & Growth Oriented Trade Recommendations - classian.co.kr
What are Karyopharm Therapeutics Inc.’s recent SEC filings showingMarket Risk Report & Reliable Entry Point Alerts - thegnnews.com
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Shares Bounce 42% But Its Business Still Trails The Industry - 富途牛牛
Can Karyopharm Therapeutics Inc. rally from current levelsWeekly Profit Analysis & Technical Pattern Recognition Alerts - Newser
Karyopharm Therapeutics Inc. stock prediction for this weekTrade Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
Advanced analytics toolkit walkthrough for Karyopharm Therapeutics Inc.Portfolio Profit Report & Verified Momentum Stock Alerts - Newser
How to read the order book for Karyopharm Therapeutics Inc.July 2025 Drop Watch & Capital Protection Trading Alerts - Newser
Published on: 2025-08-16 03:21:01 - Newser
Comparing Karyopharm Therapeutics Inc. in custom built stock radarsWeekly Market Report & Safe Capital Preservation Plans - Newser
How moving averages guide Karyopharm Therapeutics Inc. tradingPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Will Karyopharm Therapeutics Inc. Benefit From Broader Market BounceJuly 2025 Retail & Pattern Based Trade Signal System - beatles.ru
Is a relief rally coming for Karyopharm Therapeutics Inc. holders2025 Support & Resistance & Risk Controlled Swing Alerts - Newser
What makes Karyopharm Therapeutics Inc. stock attractive to long term investorsM&A Rumor & Safe Investment Capital Preservation Plans - Newser
Karyopharm's 24.5% Intraday Surge: A High-Stakes Gamble Between Cash Runway and Clinical Catalysts - AInvest
Cautious Hold on Karyopharm Therapeutics Amid Revenue Guidance Cut and Clinical Delays - TipRanks
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Why Karyopharm Therapeutics Inc. stock attracts strong analyst attention2025 Bull vs Bear & AI Powered Market Trend Analysis - Newser
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results - simplywall.st
Karyopharm Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript - Insider Monkey
Karyopharm Therapeutics (NASDAQ:KPTI) Given New $25.00 Price Target at Robert W. Baird - Defense World
Karyopharm Therapeutics shares rise 1.03% premarket after reporting Q2 earnings. - AInvest
Karyopharm Therapeutics Inc. Builds Base for Possible ReboundOversold Bounce Stock Play Ideas Gain Attention - beatles.ru
Baird Lowers Karyopharm PT to $25 from $42 Amid Patent Concerns - AInvest
Karyopharm Therapeutics Reports Q2 Loss Amid Revenue ShortfallNews and Statistics - IndexBox
Karyopharm Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... By GuruFocus - Investing.com Canada
Will Karyopharm Therapeutics Inc. see short term momentumFree Momentum Based Equity Trading Plan - Newser
Karyopharm Therapeutics Reports Q2 2025 Earnings - TipRanks
Karyopharm’s Revenue Dips As Drug Sales Inch Upward - Finimize
Karyopharm Sees Mixed Q2 As XPOVIO Sales Climb - Finimize
Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 - MSN
Karyopharm Therapeutics Sees $1B Peak Revenue Potential in Myelofibrosis by 2026 - AInvest
Karyopharm Reports Q2 2025 Financial Results, Updates Guidance, and Explores Financing and Strategic Alternatives - AInvest
Karyopharm Therapeutics Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) - Seeking Alpha
Earnings call transcript: Karyopharm Q2 2025 sees revenue decline amid strategic shifts - Investing.com Nigeria
Karyopharm Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Karyopharm Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Karyopharm Therapeutics Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Citizen Tribune
Karyopharm Q2 2025 slides: Myelofibrosis pivot amid mixed financial results By Investing.com - Investing.com South Africa
Karyopharm Q2 2025 slides: Myelofibrosis pivot amid mixed financial results - Investing.com
Karyopharm Therapeutics Q2 revenue falls 11% - MarketScreener
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics Q2 EPS Misses Estimate, Revenue Down 11.4% Y/Y - AInvest
Karyopharm Q2 rev. $37.9mln, up 6% YoY; updates FY guidance. - AInvest
Multi Factor Analysis Ranks Karyopharm Therapeutics Inc. as Strong BuyMomentum Based Equity Trading Plans Reviewed - beatles.ru
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Abate Kristin | Chief Accounting Officer |
Jul 22 '25 |
Sale |
4.00 |
238 |
952 |
9,475 |
| Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 23 '25 |
Sale |
6.17 |
419 |
2,585 |
28,853 |
| Paulson Richard A. | President and CEO |
Apr 04 '25 |
Sale |
3.74 |
245 |
916 |
82,739 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Mar 04 '25 |
Sale |
6.29 |
3,445 |
21,669 |
34,314 |
| Paulson Richard A. | President and CEO |
Mar 04 '25 |
Sale |
6.29 |
11,694 |
73,555 |
82,984 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 04 '25 |
Sale |
6.29 |
3,587 |
22,562 |
29,272 |
| Poulton Stuart | EVP, Chief Development Officer |
Mar 04 '25 |
Sale |
6.29 |
3,548 |
22,317 |
27,414 |
| Mano Michael | SVP, General Counsel&Secretary |
Mar 04 '25 |
Sale |
6.29 |
2,793 |
17,568 |
21,047 |
| Poulton Stuart | EVP, Chief Development Officer |
Feb 18 '25 |
Sale |
0.63 |
5,914 |
3,726 |
320,714 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):